In melanoma (B16-F10 and A375) cells, its ability to decrease MMP-2 and MMP-9 protein expression and suppress the Wnt/β-catenin pathway suggesting a therapeutic strategy for highly metastatic tumors [466]. This evidence concerns the gene MMP9 and melanoma.